

14 FEB 2002

Customer No. 22,852
Attorney Docket No. 03715.0104



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Elisabeth TOURNIER-LASSERVE et al.)
) Group Art Unit: Not Assigned
Serial No.: 10/019,434)
) Examiner: Not Assigned
Filed: December 31, 2001)
)
For: USE OF *KRT1* GENE IN THE)
FIELD OF ANGIOGENESIS)

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§1.56 and 1.97(b), applicant brings to the Examiner's attention the documents listed on attached Form PTO-1449 and cited in the international search report. Copies of the listed documents are attached. Applicant respectfully requests that the Examiner consider the documents listed on attached Form PTO-1449 and indicate that they were considered by making an appropriate notation on this form. This Information Disclosure Statement is being filed within three months of the filing date of the above-referenced application.

Also enclosed is an English-language international search report from the European Patent Office in the PCT international application, from which this national phase U.S. application is derived, citing these documents and setting forth the relevance thereof.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicant determines that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents. Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.


Dated: February 14, 2002

By:


Kenneth J. Meyers
Reg. No. 25,146

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	3715.0102	Serial No.	10/019,434
Applicant	Elisabeth TOURNIER-LASSERVE et al.		
Filing Date	December 31, 2001	Group:	Not assigned



U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Laberge et al.; "Familial Cavernous Angiomas CCM1 Gene Identification" <i>Eur. J. Hum. Gen.</i> ; Vol. 6; Suppl. 1; (1998) pp. 146
	Serebriiskii et al.; "Association of Krev-1/rap1a with Krit1, A Novel Ankyrin Repeat-containing Protein Encoded by a Gene Mapping to 7q21-22" <i>Oncogene</i> ; vol. 15, (1997) pp. 1043-1049
	Laberge et al.; "Genetic Heterogeneity and Absence of Founder Effect in a Series of 36 French Cerebral Cavernous Angiomas Families" <i>Eur. J. Hum. Gen.</i> ; Vol. 7, (1999) pp. 499-504
	Craig et al.; "Multilocus Linkage Identifies Two New loci for a Mendelian Form of Stroke, Cerebral Cavernous Malformation, at 7p-15-13 and 3q25.2-27" <i>Hum. Mol. Gen.</i> ; Vol. 7, No. 2, (1998) pp. 1851-1858
	Sahoo et al.; "Mutations in the Gene Encoding KRIT1, a Krev-1/rap1a Binding Protein, Cause Cerebral Cavernous Malformations (CCM1); <i>Hum. Mol. Gen.</i> ; Vol. 8, No. 12, (1999) pp. 2325-2333
	Couteulx et al.; "Truncating Mutations in CCM1, Encoding KRIT1, Cause Hereditary Cavernous Angiomas; <i>Nature Genetics</i> ; Vol. 23, No. 2, (1999) pp. 189-193

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce